Literature DB >> 1327787

In vitro evaluation of E-4695, a new fluoro-naphthyridine.

R N Jones1.   

Abstract

Compound E-4695, a C-7 azetidinyl fluoro-naphthyridine, was compared to six structurally related quinolones and was generally two- to four-fold more active than ciprofloxacin. E-4695 was particularly active against Staphylococcus aureus (MIC90 0.06 mg/l), Staphylococcus haemolyticus (MIC90 0.5 mg/l), Klebsiella spp. (MIC90 less than or equal to 0.015 mg/l), Serratia marcescens (MIC90 0.06 mg/l), Acinetobacter spp. (MIC90 less than or equal to 0.015 mg/l), Pseudomonas aeruginosa (MIC90 0.5 mg/l), Xanthomonas maltophilia (MIC90 0.5 mg/l), and Neisseria gonorrhoeae (MIC90 less than or equal to 0.001 mg/l). This new quinolone-like drug requires further investigations to confirm these promising in vitro findings.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327787     DOI: 10.1007/bf01967076

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

Review 1.  Structure-activity relationships of the fluoroquinolones.

Authors:  D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.

Authors:  D Gargallo-Viola; M Esteve; S Llovera; X Roca; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 3.  Fluoroquinolone antimicrobial agents.

Authors:  D C Hooper; J S Wolfson
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

Review 4.  New mechanisms of bacterial resistance to antimicrobial agents.

Authors:  G A Jacoby; G L Archer
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

5.  Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; M Esteve; M Moros; R Coll; M A Xicota; C de Andres; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

6.  Use of Haemophilus test medium for broth microdilution antimicrobial susceptibility testing of Streptococcus pneumoniae.

Authors:  J H Jorgensen; L A Maher; A W Howell
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

7.  In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391.

Authors:  M A Cohen; M D Huband; G B Mailloux; S L Yoder; G E Roland; C L Heifetz
Journal:  Diagn Microbiol Infect Dis       Date:  1991 May-Jun       Impact factor: 2.803

8.  Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969).

Authors:  A M Espinoza; N X Chin; A Novelli; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

9.  In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

  9 in total
  4 in total

1.  Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates.

Authors:  B B Gooding; M E Erwin; M S Barrett; D M Johnson; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.

Authors:  M S Barrett; R N Jones; M E Erwin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-02       Impact factor: 3.267

3.  E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.

Authors:  J Guinea; D Gargallo-Viola; M Robert; E Tudela; M A Xicota; J Garcia; M Esteve; R Coll; M Pares; R Roser
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 4.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.